R.SR
REGISTERED-SUPPLEMENTAL REGISTER
03/29/2022
Back to search
Official data from USPTO
ONCOLOGUES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
03/29/2022
Classification
Registered
Trademark type
Word
Nice classes
42
Filing date
05/04/2020
Registration date
03/29/2022
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/29/2022
Last transaction
03/29/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Supplemental Register
Filing basis
Intent to use
First use anywhere
2020-05-00
First use in commerce
2020-05-00
Drawing code
4
Owner type
03
Owner location
New York, NY, US
Examiner
KEAN, AMY C
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Oncogenuity, Inc.
Representatives
Devon E. White WYRICK ROBBINS YATES & PONTON LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Pharmaceutical product development services; Pharmaceutical product evaluation services; Pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of pharmaceuticals for the treatment of cancer and oncological conditions; Research and development of vaccines and medicines; Technical research in the field of pharmaceutical studies; Development of computer platform technology, namely, development of cancer immunotherapy software platforms for manufacturing therapeutics; Consulting services for others in the field of design, planning, and implementation of clinical trials; Information technology platform as Service (PaaS) featuring computer software platforms for cancer diagnosis and analysis of cancer symptoms and cancer treatment, in the medical field; Electronic data storage; Providing a bioinformatics platform as a service (PAAS) featuring computer software platforms for sequence data analysis in the field of manufacturing therapeutics; Medical and scientific research information in the field of cell therapy; Scientific research and analysis for medical purposes in the field of cancer, oncology and clinical trials
Publications
History of USPTO decisions and trademark events.
29 publications found
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/22/2022
ALIE
ASSIGNED TO LIE
02/18/2022
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
02/14/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
02/14/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/14/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
02/14/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/14/2022
AAUA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
02/12/2022
IUAA
USE AMENDMENT ACCEPTED
02/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/27/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/27/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
01/27/2022
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
01/27/2022
IUAF
USE AMENDMENT FILED
01/27/2022
EAAU
TEAS AMENDMENT OF USE RECEIVED
01/26/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
07/28/2021
GNFR
FINAL REFUSAL E-MAILED
07/28/2021
CNFR
FINAL REFUSAL WRITTEN
07/28/2021
DOCK
ASSIGNED TO EXAMINER
06/21/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/03/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/04/2020
GNRT
NON-FINAL ACTION E-MAILED
08/04/2020
CNRT
NON-FINAL ACTION WRITTEN
08/04/2020
DOCK
ASSIGNED TO EXAMINER
07/29/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/15/2020
NWAP
NEW APPLICATION ENTERED
05/07/2020
Continuous trademark protection
Get notified about every new filing that threatens ONCOLOGUES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.